Nuclear medicine growth The company has a long track record in nuclear medicine materials and is actively expanding access to lead-212 for cancer drug development across Europe, presenting a high-potential market for suppliers, partners, and contract manufacturing or distribution services.

Lead-212 partnerships Recent partnerships and LOIs with TAG1 and MORPHO Pharma indicate a strategic push to build a sustainable supply chain for radiopharmaceuticals, creating opportunities for tiered supply arrangements, logistics, and regulatory support services across Europe.

Nuclear energy transition NRG PALLAS positions itself as enabling CO2-neutral energy through nuclear technology, suggesting opportunities to sell research, testing, and irradiation services, as well as consulting or project partnerships around nuclear-based climate initiatives.

Integrated supply chain Strategic collaborations to secure independent supply chains for Lutetium-177 chloride and related materials indicate a need for end-to-end procurement, quality assurance, and regulatory-compliance services, plus potential co-development or licensing deals.

International reach With a global scope, decades of experience, and a substantial revenue base, the company is a strong candidate for enterprise services such as advanced analytics, CRM/ERP modernization, and managed services to support scalable operations and cross-border projects.